iNtRON Biotechnology, Inc. engages in the development of new biopharmaceuticals, alternatives to antibiotics for animals, and molecular diagnosis. It operates through the New Testament Part and DR Part business divisions. The company was founded on January 18, 1999 and is headquartered in Seongnam-si, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company